RAS mutations are independently associated with decreased overall survival and event-free survival in patients with AML receiving induction chemotherapy Meeting Abstract


Authors: Ball, B. J.; Hsu, M.; Devlin, S. M.; Famulare, C.; Cai, S. F.; Dunbar, A.; Epstein-Peterson, Z. D.; Menghrajani, K.; Glass, J. L.; Taylor, J.; Viny, A. D.; Goldberg, A. D.; Tallman, M. S.; Stein, E. M.
Abstract Title: RAS mutations are independently associated with decreased overall survival and event-free survival in patients with AML receiving induction chemotherapy
Meeting Title: 61st Annual Meeting of the American Society of Hematology (ASH)
Abstract: DISCLOSURES: Cai: Imago Biosciences, Inc.: Consultancy. Viny:Hematology News: Membership on an entity's Board of Directors or advisory committees; Mission Bio: Other: Sponsored travel. Goldberg:American Society of Clinical Oncology: Research Funding; Abbvie: Research Funding; ADC Therapeutics: Research Funding; American Society of Hematology: Research Funding; DAVA Oncology: Honoraria; Pfizer: Research Funding; Arog Pharmaceuticals: Research Funding; Abbvie: Consultancy; Daiichi-Sankyo: Consultancy, Research Funding; Celgene: Consultancy. Tallman:BioLineRx: Consultancy, Membership on an entity's Board of Directors or advisory committees; Biosight: Research Funding; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Rigel: Consultancy; Cellerant: Research Funding; ADC Therapeutics: Research Funding; Orsenix: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; KAHR: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees. Stein:Astellas Pharma US, Inc: Membership on an entity's Board of Directors or advisory committees; Celgene Corporation: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; PTC Therapeutics: Membership on an entity's Board of Directors or advisory committees; Syros: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo, Inc.: Membership on an entity's Board of Directors or advisory committees; Bioline: Membership on an entity's Board of Directors or advisory committees; Genentech: Membership on an entity's Board of Directors or advisory committees. © 2019 by The American Society of Hematology.
Journal Title: Blood
Volume: 134
Issue: Suppl. 1
Meeting Dates: 2019 Dec 7-10
Meeting Location: Orlando, FL
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2019-11-13
Start Page: 18
Language: English
DOI: 10.1182/blood-2019-125319
PUBMED: 31724021
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus
Altmetric Score